Table 3.
CAR-T cell and bispecific antibody single agent activity in RRMM.
| Agent Class, Name | Target | Prior Treatments, median (range) | Single Agent ORR | PFS/DOR | Label Status | |
|---|---|---|---|---|---|---|
| CAR-T Cells | Idecabtagene Vicleucel (25) | BCMA | 6 (3 - 16) | 82% | PFS 8.6 months at 24.8 months | FDA/EMA approved |
| Ciltacabtagene Autoleucel (26, 27) |
BCMA | 6 (3 - 18) | 98% | PFS 34.9 months DOR 33.9 months |
||
| P-BCMA-101 (28) | BCMA | 7 (3 - 18) | 67% | –* | FDA granted orphan drug designation | |
| Bispecific Antibodies | Teclistamab-cqyv (29) | BCMA | 5 (2 - 14) | 63% | PFS 11.3 months DOR 18.4 months at 14.1 months |
EMA approved FDA accelerated approval |
| Elranatamab-bcmm (30) | BCMA | 8* | 70% | DOR NR at 6.3 months | ||
| Talquetamab-tgvs (31) | GPRC5D | 6 (2 - 14) | 70% at 405 µg/kg | –* | ||
| Cevostamab (32) | FcHR5 | 6 (2 - 15) | 52% | –* | ||
| REG-5458 (33) | BCMA | 5 (2 - 17) | 63% | –* | ||
| ABBV-383 (34) | BCMA | 5 (3 - 15) | 68% at ≥ 40 mg | NR at 10.8 months | ||
| Zevorcabtagene autoleucel (35) | BCMA x CD3 | 4 (3 - 15) | 93% | NR at 9 months | Under clinical development | |
| CART-ddbcma (36) | BCMA x CD3 | –* | 100% | –** | ||
| Linvoseltamab-gcpt (37) | BCMA x CD3 | 5 (2 - 16) | 71%* | PFS NR DOR 29.4 months |
FDA accelerated approval | |
| PHE885 (38) | BCMA | 4 (2 - 10) | 98% | ––* | ||
CD, cluster of differentiation; CAR; chimeric antigen receptor; RRMM, relapsed and/or refractory multiple myeloma; BCMA, B-cell maturation antigen; GPRC5D, G protein–coupled receptor, class C group 5 member D; FcHR5, fragment crystallizable receptor homolog 5; Rx, treatment lines; ORR, overall response rate; PFS, progression-free survival; DOR, duration of response; ADC, antibody dependent cytotoxicity; FDA, Food and Drug Administration.
*For 200 mg dose.